We are live on ! Find out more
XRTX

XORTX Therapeutics
XRTX

6 hedge funds and large institutions have $60.2K invested in XORTX Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

14,369% more capital invested

Capital invested by funds: $416 → $60.2K (+$59.8K)

200% more funds holding

Funds holding: 2 → 6 (+4)

0.34% more ownership

Funds ownership: 0% → 0.34% (+0.34%)

Holders
6
Holders Change
+4
Holders Change %
+200%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$36.3K
2
UBS Group
UBS Group
Switzerland
+$19.6K
3
National Bank of Canada
National Bank of Canada
Quebec, Canada
+$3.55K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$628
5
Raymond James Financial
Raymond James Financial
Florida
+$472

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$35.8K +$36.3K +7,694 New
UBS Group
2
UBS Group
Switzerland
$18.8K +$19.6K +4,158 New
National Bank of Canada
3
National Bank of Canada
Quebec, Canada
$3.9K +$3.55K +752 +2,149%
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$1K +$628 +133 New
Raymond James Financial
5
Raymond James Financial
Florida
$453 +$472 +100 New
CA
6
Clearstead Advisors
Ohio
$251 – – –

XRTX Hedge Fund Activity: Q2 2025 in Review

6 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q2 2025, worth a combined $60.2K — up 14,369% from $416 a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new XRTX positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $36.3K.

  • 6 institutional investors held XORTX Therapeutics (XRTX) as of Q2 2025, up from 2 in Q1 2025.
  • Funds reported $60.2K of XORTX Therapeutics stock for Q2 2025, up 14,369% quarter-over-quarter.
  • 4 funds opened new XORTX Therapeutics positions in Q2 2025 and 0 closed out, a net change of +4 holders.
  • The largest XORTX Therapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $36.3K added.

Based on aggregated 13F filings for Q2 2025.